Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance

BackgroundOvarian cancer is the leading cause of mortality among gynecological malignancies. Carboplatin and poly (ADP-ribose) polymerase inhibitors (PARPi) are often implemented in the treatment of ovarian cancer. Homologous recombination deficient (HRD) tumors demonstrate increased sensitivity to...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yani Berckmans, Hila M. Ene, Kerem Ben-Meir, Antonia Martinez-Conde, Roxanne Wouters, Bieke Van den Ende, Sara Van Mechelen, Roni Monin, Roni Frechtel-Gerzi, Hila Gabay, Eyal Dor-On, Adi Haber, Uri Weinberg, Ignace Vergote, Moshe Giladi, An Coosemans, Yoram Palti
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2024-06-01
Serie:	Frontiers in Oncology
Soggetti:	Tumor Treating Fields (TTFields) ovarian cancer drug resistance DNA damage synthetic lethality conditional vulnerability
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1402851/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!